We used the JAK1 and JAK2 inhibitor ruxolitinib, which is approved for the treatment of myelofibrosis [64], polycythemia vera [65] and acute graft-versus-host disease [66], where it primarily exerts cytoreductive and antiproliferative effects. This evidence concerns the gene JAK2 and myelofibrosis.